Cargando…

Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients’ Survival

SIMPLE SUMMARY: Histone Deacetylases (HDACs) have been reportedly associated with tumor development and progression in several types of human malignancy, being currently investigated as potential targets of anti-cancer therapy. The aim of this study is to assess the clinical significance and prognos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levidou, Georgia, Gajdzis, Pawel, Cassoux, Nathalie, Donizy, Piotr, Masaoutis, Christos, Gajdzis, Malgorzata, Gardrat, Sophie, Pergaris, Alexandros, Danas, Eougken, Klijanienko, Jerzy, Theocharis, Stamatios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507547/ https://www.ncbi.nlm.nih.gov/pubmed/34638249 http://dx.doi.org/10.3390/cancers13194763

Ejemplares similares

EPHA2, EPHA4, and EPHA6 Expression in Uveal Melanomas: Searching for the Culprits of Neoplasia
por: Pergaris, Alexandros, et al.
Publicado: (2022)

The Prognostic Values of PARP-1 Expression in Uveal Melanoma
por: Gajdzis, Malgorzata, et al.
Publicado: (2021)

Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020)

Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors
por: Palamaris, Kostas, et al.
Publicado: (2023)

Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors
por: Pouloudi, Despoina, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Psilopatis, Iason, et al.
Publicado: (2021)

Novel Prognostic Immunohistochemical Markers in Uveal Melanoma-Literature Review
por: Gajdzis, Malgorzata, et al.
Publicado: (2021)

Extracellular Vesicles as Biomarkers Carriers in Bladder Cancer: Diagnosis, Surveillance, and Treatment
por: Georgantzoglou, Natalia, et al.
Publicado: (2021)

Unraveling the Role of Histone Variant CENP-A and Chaperone HJURP Expression in Thymic Epithelial Neoplasms
por: Levidou, Georgia, et al.
Publicado: (2022)

Unraveling the Immune Microenvironment of Thymic Epithelial Tumors: Implications for Autoimmunity and Treatment
por: Masaoutis, Christos, et al.
Publicado: (2022)

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
por: Palamaris, Kostas, et al.
Publicado: (2022)

The Clinical Impact of Death Domain-Associated Protein and Holliday Junction Recognition Protein Expression in Cancer: Unmasking the Driving Forces of Neoplasia
por: Pergaris, Alexandros, et al.
Publicado: (2023)

Searching for Novel Biomarkers in Thymic Epithelial Tumors: Immunohistochemical Evaluation of Hippo Pathway Components in a Cohort of Thymic Epithelial Tumors
por: Palamaris, Kostas, et al.
Publicado: (2023)

The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread
por: Pergaris, Alexandros, et al.
Publicado: (2021)

Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival
por: Giaginis, Constantinos, et al.
Publicado: (2015)

HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment
por: Papatheofani, Vasiliki, et al.
Publicado: (2021)

Eph Receptors and Ephrins in Retinal Diseases
por: Kaczmarek, Radoslaw, et al.
Publicado: (2021)

Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
por: Goutas, Dimitrios, et al.
Publicado: (2021)

The Role of Eph Receptors and Ephrins in Corneal Physiology and Diseases
por: Kaczmarek, Radoslaw, et al.
Publicado: (2021)

Challenging, Accurate and Feasible: CAF-1 as a Tumour Proliferation Marker of Diagnostic and Prognostic Value
por: Sykaras, Alexandros G., et al.
Publicado: (2021)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Ephrin Receptors (Ephs) Expression in Thymic Epithelial Tumors: Prognostic Implications and Future Therapeutic Approaches
por: Masaoutis, Christos, et al.
Publicado: (2021)

The Role of Exosomes in Bone Remodeling: Implications for Bone Physiology and Disease
por: Masaoutis, Christos, et al.
Publicado: (2019)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)

Utilizing Exosomal-EPHs/Ephrins as Biomarkers and as a Potential Platform for Targeted Delivery of Therapeutic Exosomes
por: Goutas, Dimitrios, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer
por: Xu, Xiaoxin S, et al.
Publicado: (2011)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

The EPH/Ephrin System in Colorectal Cancer
por: Papadakos, Stavros P., et al.
Publicado: (2022)

Clinical and Molecular Insights of Radiation-Induced Breast Sarcomas: Is There Hope on the Horizon for Effective Treatment of This Aggressive Disease?
por: Kokkali, Stefania, et al.
Publicado: (2022)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
por: Garmpis, Nikolaos, et al.
Publicado: (2022)

CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2
por: Boucheron, Nicole, et al.
Publicado: (2014)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_40qeud4g8qfh7ke8g2nmnrqsre